AUSTRALIAN-LISTED natural health company Blackmores has been named to take a key leadership advisory role for the China Association for Quality Inspection (CAQI), a "high level non-profit Chinese organisation with responsibility for product quality inspection".
The confirmation came during the Healthplex Expo in Shanghai, China where Complementary Medicines Australia (CMA) ceo Carl Gibson is leading a delegation of Australian industry leaders.
Gibson said "we welcome this appointment as an endorsement for Blackmores and for the quality and exceptional reputation of Australian complementary medicines.
"CMA would also like to congratulate Blackmores managing director, Asia, Peter Osborne, for his appointment as vice chairman of CAQI's Advisory Committee, as he will have the honour of being the first foreign citizen to hold a CAQI board position."
Blackmores and Osborne have both been appointed for five years.
Blackmores ceo Christine Holgate said the appointment reflected the importance of Australia as a trading partner with China.
CAQI vice chair Zhang Ming said Osborne was uniquely positioned to serve on the organisation's board, with 23 years of diplomatic experience with Austrade.
Holgate also announced the appointment of former Murray Goulburn senior executive Jeff Zhang as Blackmores general manager, China.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jun 17